No Data
No Data
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference
VistaGen Therapeutics | 10-Q: Q1 2025 Earnings Report
Express News | VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate
Express News | Vistagen Therapeutics Inc - Palisade Phase 3 Program for Acute Treatment of Social Anxiety Disorder Progressing on Track